Axxcess Wealth Management LLC Has $429,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Axxcess Wealth Management LLC raised its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 15.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,171 shares of the company’s stock after purchasing an additional 2,569 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Intellia Therapeutics were worth $429,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Blue Trust Inc. boosted its holdings in shares of Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after acquiring an additional 1,398 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after acquiring an additional 472 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Intellia Therapeutics by 1,322.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock worth $59,000 after acquiring an additional 2,459 shares in the last quarter. EntryPoint Capital LLC boosted its holdings in shares of Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after acquiring an additional 1,563 shares in the last quarter. Finally, AdvisorNet Financial Inc boosted its holdings in shares of Intellia Therapeutics by 63.5% in the 2nd quarter. AdvisorNet Financial Inc now owns 5,100 shares of the company’s stock worth $114,000 after acquiring an additional 1,980 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Trading Down 4.6 %

NTLA stock opened at $21.88 on Friday. Intellia Therapeutics, Inc. has a 1-year low of $19.21 and a 1-year high of $34.87. The business’s 50-day moving average price is $23.26 and its two-hundred day moving average price is $24.16. The firm has a market cap of $2.11 billion, a PE ratio of -4.08 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. During the same quarter in the previous year, the business earned ($1.40) EPS. Intellia Therapeutics’s quarterly revenue was down 48.5% compared to the same quarter last year. On average, analysts forecast that Intellia Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NTLA. Stifel Nicolaus reduced their target price on Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 price objective on shares of Intellia Therapeutics in a report on Thursday, June 27th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $54.00 price objective on shares of Intellia Therapeutics in a report on Thursday. Finally, StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $61.77.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.